<DOC>
	<DOCNO>NCT00734383</DOCNO>
	<brief_summary>The purpose study determine intravenous anesthetic antioxidant property protect heart diabetic patient injury undergoing coronary bypass surgery .</brief_summary>
	<brief_title>Propofol Cardioprotection Type II Diabetics</brief_title>
	<detailed_description>Diabetic patient elevate risk low cardiac output syndrome . This high risk scenario adversely affect 26 % patient recover cardiac surgery . Aggressive hemodynamic treatment require , prove inadequate . Low cardiac output syndrome quadruple overall mortality rate aortocoronary bypass surgery 2 % 8 % . Therefore , urgent need exists effective form preemptive cardioprotection antioxidant protection may play crucial role . Our research therapeutic potential propofol , intravenous anesthetic antioxidant property , could significant impact outcome select population . The propose study represent novel therapeutic approach prevention myocardial ischemia-reperfusion injury diabetic patient undergo cardiac surgery cardiopulmonary bypass . RESEARCH PLAN Two blind , randomize control phase II study conduct patient undergo primary aortocoronary bypass surgery . STUDY A Specific Aims : 1 . To determine whether propofol increase nitric oxide bioavailability decrease ET-1 formation diabetic patient undergo aortocoronary bypass surgery 2 . To determine whether propofol inhibits superoxide formation downregulates iNOS gene expression cardiac tissue . Hypothesis : Oxidant stress myocardial reperfusion promotes conversion NO cardiotoxic free radical , peroxynitrite , enhance formation vasoconstrictor ET-1 diabetic patient . We postulate factor cause postoperative cardiac dysfunction ischemic-reperfused diabetic heart . STUDY B Specific Aim : To determine whether high dose intravenous insulin increase effect propofol perioperative oxidative stress . Hypothesis : Insulin , prevent hyperglycemia , enhance propofol 's effect oxidative stress . Methods In Study A , 144 patient ( 72 patient Type II DM + 72 patient DM ) randomize receive either propofol 120 ug/kg/min isoflurane 0.5 2 % treatment interval 120 150 min ( 10 min CPB , 15 min follow aortic declamping ) . All patient receive continuous intravenous ( I.V . ) infusion insulin need maintain glucose level 8 12 mmol/L . In Study B , 72 Type II diabetic patient randomize isoflurane propofol cardioprotection . All patient treat perioperative hyperinsulinemic clamp maintain blood glucose level within target range 4.5 - 6 mmol/L 6 hour follow release aortic crossclamp . Arterial coronary sinus blood sample simultaneously initiation CPB 5 min reperfusion Troponin I , 15-F2t-isoP , nitrotyrosine tyrosine , ET-1 , TNF-alpha . An index myocardial derive 15-F2t-isoP peroxynitrite determine Cs-Ao difference percentage ratio plasma free 15-F2t-isoP nitrotyrosine tyrosine , respectively . Atrial tissue sample initiation CPB 15min reperfusion detection iNOS , eNOS superoxide formation . This coincide central venous blood sample measurement concentration propofol . The level 15-F2t-isoP , nitrotyrosine tyrosine , ET-1 , TNF-alpha blood determine 2 hour postoperatively . Troponin I level determine 2 , 12 , 24 hour postoperatively . Cardiac function assess 6 hour postoperatively pulmonary artery catheter transesophageal echocardiography . This study represent novel therapeutic approach prevention myocardial ischemia-reperfusion injury . This study diabetic patient provide prerequisite knowledge randomize clinical trial power detect clinical outcome high risk patient population .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<criteria>1 . Patients without Type II Diabetes Mellitus 2 . Hemodynamically Stable 3 . Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass 1 . Age le 18 great 80 year age 2. refuse inform consent 3 . Coexisting valvular heart disease 4 . Acute evolve myocardial infarction 5. hypersensitivity propofol formulation component 6 . Use NSAIDs , Vitamins C E within 5 7 day surgery</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>coronary artery bypass surgery</keyword>
	<keyword>coronary artery bypass grafting</keyword>
	<keyword>cardiopulmonary bypass</keyword>
	<keyword>diabetes</keyword>
	<keyword>myocardial injury marker ,</keyword>
	<keyword>sex difference</keyword>
	<keyword>cardiac anesthesia</keyword>
	<keyword>inhalational anesthetic</keyword>
</DOC>